ATYR Q3 2025 Earnings — aTyr Pharma, Inc. Revenue & Financial Results | Market Cap Arena

ATYRaTyr Pharma, Inc.

$93M

Q3 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$190,000

Gross Profit

-$22M-11547.4% margin

Operating Income

-$27M-14076.3% margin

Net Income

-$26M-13549.5% margin

EPS (Diluted)

$-0.26

QoQ Revenue Growth

+Infinity%

Cash Flow

Operating Cash Flow

-$20M

Free Cash Flow

-$21M

Stock-Based Comp.

$1M

Balance Sheet

Total Assets

$107M

Total Liabilities

$27M

Stockholders' Equity

$80M

Cash & Equivalents

$6M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$190,000	$0	—
Gross Profit	-$22M	$0	—
Operating Income	-$27M	-$18M	-47.4%
Net Income	-$26M	-$17M	-49.2%

Revenue Segments

Collaboration Revenue

$200,000100%